A Phase 2 interventional study of JNJ-70033093 25 mg and JNJ-70033093 50 mg in Arthroplasty, Replacement, Knee, sponsored by Janssen Research & Development, LLC. Completed at 117 sites in 18 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the efficacy of JNJ-70033093 in preventing total venous thromboembolism (VTE) events (proximal and/or distal deep vein thrombosis [DVT] [asymptomatic confirmed by venography assessment or objectively confirmed symptomatic], nonfatal pulmonary embolism [PE], or any death) during the treatment period.
JNJ-70033093 is an oral anticoagulant for prevention and treatment of thromboembolic events (for example, VTE) that binds and inhibits activated form of human coagulation Factor XI (FXIa) with high affinity and selectivity. The study will consist of 3 phases: up to 30-day screening phase before total knee replacement (TKR) surgery, 10 to14 day postoperative dosing phase, and 4-week follow-up phase. The hypothesis of this study is JNJ-70033093 reduces risk of total VTE during treatment period. The total duration of participation following randomization will be approximately 6 weeks. Efficacy evaluations include unilateral venography assessment of operated leg and assessments of symptomatic DVT, PE, or death. Safety evaluation includes adverse events, clinical laboratory tests, and physical examinations. The safety and efficacy will be monitored throughout the study.
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive JNJ-70033093 25 milligram (mg) (1\*25 mg capsule) and 1 placebo capsule twice daily (BID), orally for 10 to 14 postoperative days.
Drug: JNJ-70033093 25 mg · Drug: Placebo
Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules) BID orally for 10 to 14 postoperative days.
Drug: JNJ-70033093 50 mg
Participants will receive JNJ-70033093 100 mg (1\*100 mg capsule) and 1 placebo capsule BID orally for 10 to 14 postoperative days.
Drug: JNJ-70033093 100 mg · Drug: Placebo
Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules) BID orally for 10 to 14 postoperative days.
Drug: JNJ-70033093 200 mg
Participants will receive JNJ-70033093 25 mg (1\*25 mg capsule) once daily and 1 placebo capsule in the morning and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
Drug: JNJ-70033093 25 mg · Drug: Placebo
Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
Drug: JNJ-70033093 200 mg · Drug: Placebo
Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
Drug: JNJ-70033093 50 mg · Drug: Placebo
Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
Drug: Enoxaparin 40 mg
Participants will receive JNJ-70033093 25 mg (1\*25 mg capsule) BID (in Group A) or once daily (in Group E), orally for 10 to 14 postoperative days.
Also known as: BMS-986177
Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules) BID orally for 10 to 14 postoperative days.
Also known as: BMS-986177
Participants will receive JNJ-70033093 100 mg (1\*100 mg capsule) BID, orally for 10 to 14 postoperative days.
Also known as: BMS-986177
Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules) BID (in Group D) or once daily (in Group F), orally for 10 to 14 postoperative days.
Also known as: BMS-986177
Participants will receive placebo matching to JNJ-70033093, orally.
Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
Number of Participants With Total Venous Thromboembolism (VTE) (CEC-adjudicated)
Total VTE was defined as the composite of clinical events committee (CEC)-adjudicated proximal and/or distal Deep Vein Thrombosis (DVT) (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal pulmonary embolism (PE), or any death.
Time frame: Up to Day 14
Number of Participants With Any Bleeding Event (CEC-adjudicated)
Any bleeding was defined as the composite of major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria modified for the surgical setting, clinically relevant nonmajor bleeding events, or minimal bleeding events as assessed by the CEC.
Time frame: Up to Day 14; Up to Day 52
Number of Participants With Total VTE (CEC-adjudicated)
Total VTE was defined as the composite of (CEC-adjudicated) proximal and/or DVT (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal PE, or any death.
Time frame: Up to Day 52
Number of Participants With Composite of Major and Clinically Relevant Nonmajor Bleeding (CRNM) Events (CEC-adjudicated)
Composite of Major bleeding event (BE): Fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hemoglobin (Hb) level of 20 grams per liter (g/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; surgical site bleeding that requires second intervention open, arthroscopic, endovascular,or hemarthrosis resulting in prolonged hospitalization, deep wound infection and/or either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: Epistaxis, Gastrointestinal bleed,Hematuria,Bruising/ecchymosis,Hemoptysis,Hematoma.
Time frame: Up to Day 14, Up to Day 52
Number of Participants With Major Bleeding Events (CEC-adjudicated)
Number of participants with major BE (adjudicated by CEC) were reported. Major Bleeding events were defined as: fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hb level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability.
Time frame: Up to Day 14; Up to Day 52
Number of Participants With CRNM Bleeding Events (CEC-adjudicated)
Number of participants with CRNM bleeding events (adjudicated by CEC) were reported. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma.
Time frame: Up to Day 14; Up to Day 52
Number of Participants With Minimal Bleeding Events (CEC-adjudicated)
Number of participants with minimal bleeding events (adjudicated by CEC) were reported. Minimal bleeding event was defined as any bleeding event not met major or CRNM criteria. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma.
Time frame: Up to Day 14; Up to Day 52
Number of Participants With Major or CRNM Bleeding Events (CEC-adjudicated)
Major Bleeding events were defined as: fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hb level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma.
Time frame: Up to Day 14; Up to Day 52
Number of Participants With Major VTE (CEC-adjudicated)
Number of participants with major VTE (adjudicated by CEC) were reported. Major VTE was defined as a composite of proximal DVT (asymptomatic confirmed by venography or objectively confirmed symptomatic), nonfatal PE, or any death.
Time frame: Up to Day 52
Number of Participants With Major VTE (CEC-adjudicated)
Number of participants with major VTE (adjudicated by CEC) were reported. Major VTE was defined as a composite of proximal DVT (asymptomatic confirmed by venography or objectively confirmed symptomatic), nonfatal PE, or any death.
Time frame: Up to Day 14
Number of Participants With Proximal Deep Vein Thrombosis (DVT) (CEC-adjudicated)
Number of participants with proximal DVT (adjudicated by CEC) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.
Time frame: Up to Day 14
Number of Participants With Proximal DVT (CEC-adjudicated)
Number of participants with proximal DVT (CEC-adjudicated) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.
Time frame: Up to Day 52
Number of Participants With Distal DVT (CEC-adjudicated)
Number of participants with distal DVT (CEC-adjudicated) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.
Time frame: Up to Day 14
Number of Participants With Distal DVT (CEC-adjudicated)
Number of participants with distal DVT (adjudicated by CEC) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.
Time frame: Up to Day 52
Number of Participants With Nonfatal Pulmonary Embolism (PE) (CEC-adjudicated)
Number of participants with nonfatal PE (adjudicated by CEC) were reported.
Time frame: Up to Day 14
Number of Participants With Nonfatal Pulmonary Embolism (PE) (CEC-adjudicated)
Number of participants with nonfatal PE (adjudicated by CEC) were reported.
Time frame: Up to Day 52
Number of Participants With Deaths (CEC-adjudicated)
Number of participants with deaths (CEC-adjudicated) were reported.
Time frame: Up to Day 14
Number of Participants With Deaths (CEC-adjudicated)
Number of participants with deaths (CEC-adjudicated) were reported.
Time frame: Up to Day 52
Apparent Clearance (CL/F) of JNJ-70033093
Apparent clearance of a drug was defined as a measure of the rate at which a drug got metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Time frame: Up to Day 14
Apparent Volume of Distribution (V/F) of JNJ-70033093
V/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug.
Time frame: Up to Day 14
Impact of Selected Demographics: Apparent Clearance (CL/F) Based on Sex
Impact of demographic character (sex) on CL/F was assessed.
Time frame: Up to Day 14
Impact of Selected Demographic: Age on CL/F
Impact of age on CL/F was assessed.
Time frame: Up to Day 14
Impact of Selected Demographic: Weight on CL/F
Impact of weight on CL/F was assessed.
Time frame: Up to Day 14
Impact of Selected Laboratory Values: Renal Function on CL/F
Impact of renal function on CL/F was assessed. The outcome measure was reported based on CRCL.
Time frame: Up to Day 14
Impact of Selected Demographics: Sex on Apparent Volume of Distribution (V/F)
Impact of sex on V/F was assessed.
Time frame: Up to Day 14
Impact of Selected Demographics : Age on V/F
Impact of age on V/F was assessed.
Time frame: Up to Day 14
Impact of Selected Demographics : Weight on V/F
Impact of weight on V/F was assessed.
Time frame: Up to Day 14
Impact of Selected Laboratory Values: Renal Function on V/F
Impact of renal function on V/F was assessed. The outcome measure is reported based on CRCL.
Time frame: Up to Day 14
Trend Test for Primary Efficacy Event Rate (CEC Adjudicated) by Multiple Comparison Procedure - Modelling (MCP-Mod) Approach
The dose-response trend test based on the MCP-Mod framework consisted of contrast tests defined by prespecified candidate models (4 Emax dose-response models with varying degrees of ED50). Each model was evaluated for significance of trend, based on its optimal contrast, resulting in four t-test statistics, one for each candidate model. The t-test statistics were adjusted for the fact that 4 candidate models were included in the trend testing. The dose response of the drug was then established if the maximum of the t-test statistics exceeded the 95th percentile critical value. Here 'number' signifies the estimated response rate.
Time frame: Up to 14 days
Trend Test for the Composite of On-Treatment Major and Clinically Relevant Nonmajor Bleeding (CEC Adjudicated) by MCP-Mod Approach
The dose-response trend test based on the MCP-Mod framework consisted of contrast tests defined by prespecified candidate models (4 Emax dose-response models with varying degrees of ED50). Each model was evaluated for significance of trend, based on its optimal contrast, resulting in four t-test statistics, one for each candidate model. The t-test statistics were adjusted for the fact that 4 candidate models were included in the trend testing. The dose response of the drug was then established if the maximum of the t-test statistics exceeded the 95th percentile critical value. Here 'number' signifies the estimated response rate.
Time frame: Up to 14 days
| Milestone | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Started | 34 | 150 | 153 | 150 | 149 | 152 | 153 | 301 |
| Safety analysis set | 33 | 150 | 148 | 148 | 147 | 149 | 148 | 296 |
| Completed | 34 | 149 | 151 | 149 | 147 | 150 | 151 | 299 |
| Not completed | 0 | 1 | 2 | 1 | 2 | 2 | 2 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 | 1 | 2 | 2 | 2 | 1 |
Total VTE was defined as the composite of clinical events committee (CEC)-adjudicated proximal and/or distal Deep Vein Thrombosis (DVT) (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal pulmonary embolism (PE), or any death.
| Participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Total Venous Thromboembolism (VTE) (CEC-adjudicated) | 7 | 30 | 27 | 14 | 8 | 12 | 10 | 54 |
Any bleeding was defined as the composite of major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria modified for the surgical setting, clinically relevant nonmajor bleeding events, or minimal bleeding events as assessed by the CEC.
| Participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Up to Day 14 | 0 | 8 | 2 | 7 | 11 | 7 | 6 | 12 |
| Up to Day 52 | 0 | 8 | 2 | 7 | 11 | 7 | 6 | 12 |
Total VTE was defined as the composite of (CEC-adjudicated) proximal and/or DVT (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal PE, or any death.
| Participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Total VTE (CEC-adjudicated) | 7 | 30 | 27 | 14 | 8 | 12 | 10 | 54 |
Composite of Major bleeding event (BE): Fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hemoglobin (Hb) level of 20 grams per liter (g/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; surgical site bleeding that requires second intervention open, arthroscopic, endovascular,or hemarthrosis resulting in prolonged hospitalization, deep wound infection and/or either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: Epistaxis, Gastrointestinal bleed,Hematuria,Bruising/ecchymosis,Hemoptysis,Hematoma.
| Participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Up to Day 14 | 0 | 2 | 0 | 2 | 1 | 1 | 1 | 5 |
| Up to Day 52 | 0 | 2 | 0 | 2 | 2 | 1 | 1 | 5 |
Number of participants with major BE (adjudicated by CEC) were reported. Major Bleeding events were defined as: fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hb level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability.
| Participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Up to Day 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Up to Day 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Number of participants with CRNM bleeding events (adjudicated by CEC) were reported. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma.
| Participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Up to Day 14 | 0 | 2 | 0 | 2 | 1 | 1 | 1 | 4 |
| Up to Day 52 | 0 | 2 | 0 | 2 | 2 | 1 | 1 | 4 |
Number of participants with minimal bleeding events (adjudicated by CEC) were reported. Minimal bleeding event was defined as any bleeding event not met major or CRNM criteria. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma.
| Participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Up to Day 14 | 0 | 6 | 2 | 5 | 8 | 7 | 4 | 8 |
| Up to Day 52 | 0 | 6 | 2 | 5 | 9 | 7 | 5 | 8 |
Major Bleeding events were defined as: fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hb level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma.
| Participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Up to Day 14 | 0 | 2 | 0 | 2 | 1 | 1 | 1 | 5 |
| Up to Day 52 | 0 | 2 | 0 | 2 | 2 | 1 | 1 | 5 |
Number of participants with major VTE (adjudicated by CEC) were reported. Major VTE was defined as a composite of proximal DVT (asymptomatic confirmed by venography or objectively confirmed symptomatic), nonfatal PE, or any death.
| Participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Major VTE (CEC-adjudicated) | 0 | 2 | 1 | 1 | 0 | 2 | 0 | 4 |
Number of participants with major VTE (adjudicated by CEC) were reported. Major VTE was defined as a composite of proximal DVT (asymptomatic confirmed by venography or objectively confirmed symptomatic), nonfatal PE, or any death.
| Participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Major VTE (CEC-adjudicated) | 0 | 2 | 1 | 1 | 0 | 2 | 0 | 4 |
Number of participants with proximal DVT (adjudicated by CEC) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.
| Participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Asymptomatic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Symptomatic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with proximal DVT (CEC-adjudicated) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.
| Participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Asymptomatic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Symptomatic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with distal DVT (CEC-adjudicated) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.
| Participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Asymptomatic | 7 | 27 | 26 | 13 | 8 | 10 | 10 | 50 |
| Symptomatic | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 |
Number of participants with distal DVT (adjudicated by CEC) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.
| Participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Asymptomatic | 7 | 27 | 26 | 13 | 8 | 10 | 10 | 50 |
| Symptomatic | 0 | 2 | 2 | 0 | 0 | 1 | 0 | 0 |
Number of participants with nonfatal PE (adjudicated by CEC) were reported.
| Participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Nonfatal Pulmonary Embolism (PE) (CEC-adjudicated) | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 |
Number of participants with nonfatal PE (adjudicated by CEC) were reported.
| Participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Nonfatal Pulmonary Embolism (PE) (CEC-adjudicated) | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 |
Number of participants with deaths (CEC-adjudicated) were reported.
| Participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Deaths (CEC-adjudicated) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Number of participants with deaths (CEC-adjudicated) were reported.
| Participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Deaths (CEC-adjudicated) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Apparent clearance of a drug was defined as a measure of the rate at which a drug got metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
| Liter per hour (L/h) | Overall |
|---|---|
| Apparent Clearance (CL/F) of JNJ-70033093 | 7.72 ± 39.5 |
V/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug.
| Liter | Overall |
|---|---|
| Apparent Volume of Distribution (V/F) of JNJ-70033093 | 125 ± 60.5 |
Impact of demographic character (sex) on CL/F was assessed.
| Liter per hour (L/h) | Female | Male |
|---|---|---|
| Impact of Selected Demographics: Apparent Clearance (CL/F) Based on Sex | 7.14 ± 38.5 | 9.32 ± 34.2 |
Impact of age on CL/F was assessed.
| L/h | Age: Less Than or Equal to (<=) 68 Years | Age: Greater Than (>) 68 Years |
|---|---|---|
| Impact of Selected Demographic: Age on CL/F | 8.70 ± 36.9 | 6.83 ± 37.7 |
Impact of weight on CL/F was assessed.
| L/h | Weight: <= 82 Kilograms (kg) | Weight: Greater Than (>) 82 kg |
|---|---|---|
| Impact of Selected Demographic: Weight on CL/F | 7.04 ± 37.9 | 8.54 ± 38.4 |
Impact of renal function on CL/F was assessed. The outcome measure was reported based on CRCL.
| L/h | Creatinine Clearance (CRCL): Less Than (<) 90 | CRCL: Greater Than or Equal to (>=) 90 |
|---|---|---|
| Impact of Selected Laboratory Values: Renal Function on CL/F | 6.71 ± 38.1 | 8.83 ± 35.1 |
Impact of sex on V/F was assessed.
| Liters | Female | Male |
|---|---|---|
| Impact of Selected Demographics: Sex on Apparent Volume of Distribution (V/F) | 118 ± 61.2 | 143 ± 56.0 |
Impact of age on V/F was assessed.
| Liters | AGE <= 68 Years | AGE >68 Years |
|---|---|---|
| Impact of Selected Demographics : Age on V/F | 135 ± 59.5 | 116 ± 60.3 |
Impact of weight on V/F was assessed.
| Liters | Weight <= 82kg | Weight > 82kg |
|---|---|---|
| Impact of Selected Demographics : Weight on V/F | 109 ± 58.8 | 145 ± 57.5 |
Impact of renal function on V/F was assessed. The outcome measure is reported based on CRCL.
| Liters | CRCL < 90 | CRCL >= 90 |
|---|---|---|
| Impact of Selected Laboratory Values: Renal Function on V/F | 116 ± 62.2 | 135 ± 58.5 |
The dose-response trend test based on the MCP-Mod framework consisted of contrast tests defined by prespecified candidate models (4 Emax dose-response models with varying degrees of ED50). Each model was evaluated for significance of trend, based on its optimal contrast, resulting in four t-test statistics, one for each candidate model. The t-test statistics were adjusted for the fact that 4 candidate models were included in the trend testing. The dose response of the drug was then established if the maximum of the t-test statistics exceeded the 95th percentile critical value. Here 'number' signifies the estimated response rate.
| proportion of participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID |
|---|---|---|---|---|---|---|---|
| Trend Test for Primary Efficacy Event Rate (CEC Adjudicated) by Multiple Comparison Procedure - Modelling (MCP-Mod) Approach | 0.35 (0.17 to 0.52) | 0.21 (0.16 to 0.25) | 0.20 (0.15 to 0.24) | 0.13 (0.10 to 0.16) | 0.09 (0.07 to 0.12) | 0.09 (0.06 to 0.11) | 0.07 (0.03 to 0.10) |
The dose-response trend test based on the MCP-Mod framework consisted of contrast tests defined by prespecified candidate models (4 Emax dose-response models with varying degrees of ED50). Each model was evaluated for significance of trend, based on its optimal contrast, resulting in four t-test statistics, one for each candidate model. The t-test statistics were adjusted for the fact that 4 candidate models were included in the trend testing. The dose response of the drug was then established if the maximum of the t-test statistics exceeded the 95th percentile critical value. Here 'number' signifies the estimated response rate.
| proportion of participants | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID |
|---|---|---|---|---|---|---|---|
| Trend Test for the Composite of On-Treatment Major and Clinically Relevant Nonmajor Bleeding (CEC Adjudicated) by MCP-Mod Approach | 0.02 (0.00 to 0.17) | 0.01 (0.00 to 0.03) | 0.01 (0.00 to 0.04) | 0.01 (0.00 to 0.02) | 0.01 (0.00 to 0.02) | 0.01 (0.00 to 0.02) | 0.01 (0.00 to 0.02) |
Collected over Up to 6 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 0/33 (0%) | 1/33 (3%) | 0/33 (0%) |
| JNJ-70033093 50 mg Once Daily + Placebo | 0/150 (0%) | 2/150 (1.3%) | 6/150 (4%) |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0/148 (0%) | 5/148 (3.4%) | 9/148 (6.1%) |
| JNJ-70033093 50 mg BID | 0/148 (0%) | 5/148 (3.4%) | 8/148 (5.4%) |
| JNJ-70033093 200 mg Once Daily + Placebo | 0/147 (0%) | 2/147 (1.4%) | 3/147 (2%) |
| JNJ-70033093 100 mg + Placebo BID | 0/149 (0%) | 5/149 (3.4%) | 4/149 (2.7%) |
| JNJ-70033093 200 mg BID | 0/148 (0%) | 2/148 (1.4%) | 3/148 (2%) |
| Enoxaparin 40 mg Once Daily | 1/296 (0.3%) | 11/296 (3.7%) | 17/296 (5.7%) |
| Event | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| Deep Vein ThrombosisVascular disorders | 1/33 | 1/150 | 1/148 | 1/148 | 0/147 | 2/149 | 0/148 | 0/296 |
| VomitingGastrointestinal disorders | 0/33 | 0/150 | 0/148 | 0/148 | 1/147 | 0/149 | 0/148 | 0/296 |
| Cardiovascular EvaluationInvestigations | 0/33 | 0/150 | 0/148 | 0/148 | 1/147 | 0/149 | 0/148 | 0/296 |
| Atrial FibrillationCardiac disorders | 0/33 | 0/150 | 1/148 | 0/148 | 0/147 | 0/149 | 0/148 | 0/296 |
| Non-Cardiac Chest PainGeneral disorders | 0/33 | 0/150 | 1/148 | 0/148 | 0/147 | 0/149 | 0/148 | 0/296 |
| UrosepsisInfections and infestations | 0/33 | 0/150 | 1/148 | 0/148 | 0/147 | 0/149 | 0/148 | 0/296 |
| ContusionInjury, poisoning and procedural complications | 0/33 | 0/150 | 0/148 | 1/148 | 0/147 | 0/149 | 0/148 | 0/296 |
| Periprosthetic FractureInjury, poisoning and procedural complications | 0/33 | 0/150 | 0/148 | 1/148 | 0/147 | 0/149 | 0/148 | 0/296 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/33 | 0/150 | 0/148 | 0/148 | 0/147 | 0/149 | 1/148 | 0/296 |
| Compartment SyndromeMusculoskeletal and connective tissue disorders | 0/33 | 0/150 | 0/148 | 1/148 | 0/147 | 0/149 | 0/148 | 0/296 |
| Event | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily |
|---|---|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/33 | 6/150 | 9/148 | 8/148 | 3/147 | 4/149 | 3/148 | 17/296 |
| Age, Continuous(years) | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 68.1 ± 5.74 | 67.9 ± 8.03 | 68.4 ± 8.49 | 68.8 ± 8.17 | 68 ± 8.25 | 67 ± 8 | 68.6 ± 7.76 | 67.8 ± 7.97 | 68 ± 8.02 |
| Sex: Female, Male(Participants) | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 24 | 107 | 113 | 108 | 108 | 102 | 106 | 208 | 876 |
| Male | 10 | 43 | 40 | 42 | 41 | 50 | 47 | 93 | 366 |
| Ethnicity (NIH/OMB)(Participants) | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 21 | 19 | 20 | 20 | 14 | 14 | 42 | 156 |
| Not Hispanic or Latino | 28 | 121 | 126 | 125 | 125 | 129 | 133 | 250 | 1037 |
| Unknown or Not Reported | 0 | 8 | 8 | 5 | 4 | 9 | 6 | 9 | 49 |
| Race (NIH/OMB)(Participants) | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| Asian | 0 | 22 | 17 | 16 | 17 | 16 | 16 | 32 | 136 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 4 |
| Black or African American | 0 | 1 | 2 | 1 | 0 | 3 | 1 | 4 | 12 |
| White | 34 | 124 | 134 | 132 | 129 | 132 | 136 | 260 | 1081 |
| More than one race | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 2 | 6 |
| Region of Enrollment(Participants) | JNJ-70033093 25 mg Once Daily + Placebo | JNJ-70033093 50 mg Once Daily + Placebo | JNJ-70033093 25 mg + Placebo Twice Daily (BID) | JNJ-70033093 50 mg BID | JNJ-70033093 200 mg Once Daily + Placebo | JNJ-70033093 100 mg + Placebo BID | JNJ-70033093 200 mg BID | Enoxaparin 40 mg Once Daily | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asia | 0 | 22 | 16 | 16 | 16 | 16 | 16 | 32 | 134 |
| Europe | 21 | 55 | 65 | 65 | 64 | 64 | 65 | 129 | 528 |
| South America | 0 | 9 | 7 | 6 | 7 | 7 | 6 | 13 | 55 |
| North America | 5 | 19 | 20 | 19 | 19 | 19 | 21 | 38 | 160 |
| Western Europe | 8 | 45 | 45 | 44 | 43 | 46 | 45 | 89 | 365 |
Showing the first 100 of 117 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinicaltrials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Jun 2019 to primary completion in Apr 2021, 21 months.
Results were first posted in Jul 2022, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Milvexian
Janssen Research & Development, LLC →